In the US, among women at high risk for acquiring HIV infection, only around 2% have initiated PrEP. What are the patient, provider, and system barriers to increased PrEP uptake in this vulnerable population? What can clinicians do to overcome these barriers?
In this issue, Dr. Rachel Scott, Scientific Director of Women’s Health Research at the MedStar Health Research Institute and Assistant Professor of Obstetrics and Gynecology at the Georgetown University School of Medicine, provides some answers.
People who inject drugs (PWID) are at risk for HIV infection from both sexual- as well as injection-related causes. What can clinicians do to reduce the incidence of infection and improve their patients’ health? In this issue, Dr. Jessica Taylor from The Boston University School of Medicine and Boston Medical Center takes us into the clinic to explain how current evidence-based strategies can increase the uptake of HIV pre-exposure prophylaxis in this vulnerable population.
In her recent newsletter issue (eHIV Review V5 #1), Dr. Ethel Weld, Assistant Professor of Medicine, Pharmacology and Molecular Sciences at the Johns Hopkins School of Medicine, analyzed the current research about the potential uses of two-drug ART regimens. Join her now for a case-based discussion about how that new information can affect patient selection in the clinic.
“U=U” — an Undetectable HIV viral load means Untransmittable HIV virus. In her recent eHIV Newsletter Issue (Vol. 4; No. 11), Dr. Jill Blumenthal from the Division of Infectious Diseases and Global Public Health at the University of California San Diego analyzed the current evidence strongly supporting this concept. In this Podcast, she discusses “U=U” from the clinical perspective, and models how it can help promote patient safety.
In this Issue, Dr. Joyce Jones from the Johns Hopkins University School of Medicine and Dr. Barbara Taylor from the University of Texas Health Science Center at San Antonio analyze recent publications describing evidence-based ART adherence interventions and how they can be tailored to specific situations to increase effectiveness.
While newer antiviral agents like darunavir and the integrase strand transfer inhibitor (INSTI) dolutegravir have shown great efficacy, recent postmarketing surveillance has identified important adverse effects not found in the clinical trial populations.
In this issue, Dr. Cody Chastain from the Division of Infectious Diseases at Vanderbilt University Medical Center discusses how these new findings can impact the clinical use of these new agents.
Linking high-risk populations like PWIDs (people who inject drugs) and MSM (men who have sex with men) to effective HIV care requires overcoming complex barriers unique to these groups.
In this issue, two of the directors from Boston’s Health Care for the Homeless Program, Dr. Jennifer Brody, Director of HIV Services and ANP Marguerite Beiser, Director of HCV Services, discuss the clinical aspects of addressing these challenges.
The incidence of the metabolic complications common in people with HIV infection — bone disease, weight gain, cardiovascular disease, and liver disease — is increasing as improved antiretroviral therapies create longer lifespans.
In this issue, Dr. Suman Srinivasa and nurse practitioner Kathleen Fitch from Harvard Medical School discuss how to identify and manage these metabolic complications to help improve outcomes and quality of life in patients living with HIV.
Recently approved treatment options and new antiviral therapies still under investigation — through case-based discussion, Dr. Ethel Weld from the Division of Clinical Pharmacology and Infectious Diseases at the Johns Hopkins University School of Medicine explains how the promise of these new agents can impact current clinical practice.